We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+2.33%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$95.2M
AUM Growth
+$3.46M
Cap. Flow
+$2.54M
Cap. Flow %
2.66%
Top 10 Hldgs %
72.22%
Holding
42
New
7
Increased
9
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
ANIP icon
ANI Pharmaceuticals
ANIP
+$7.44M
2
QLTI
QLT Inc
QLTI
+$4.59M
3
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$1.91M
4
ABBV icon
AbbVie
ABBV
+$1.63M
5
AORT icon
Artivion
AORT
+$1.58M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$6.23M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$3.86M
3
TWM icon
ProShares UltraShort Russell2000
TWM
+$3.51M
4
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$964K
5
DGX icon
Quest Diagnostics
DGX
+$812K

Sector Composition

Rank Sector Weight
1 Healthcare 66.02%
2 Miscellaneous 33.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRI
1
DELISTED
Albany Molecular Research Inc
AMRI
$11.5M 12.05%
567,400
+25,000
+5% +$482K
QLTI
2
DELISTED
QLT Inc
QLTI
$8.7M 9.14%
2,107,200
+1,195,000
+131% +$4.59M
BIS icon
3
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$8.62M 9.05%
37,500
+34,375
+1,100% +$8.53M
MNKD icon
4
PUT
MannKind Corp
MNKD
$1.31B
$8.36M 8.78%
294,000
+194,000
+194% +$4.96M
ANIP icon
5
ANI Pharmaceuticals
ANIP
$1.69B
$7.76M 8.15%
+125,000
New +$7.44M
AZN icon
6
AstraZeneca
AZN
$255B
$6.37M 6.69%
100,000
– –
PFE icon
7
Pfizer
PFE
$160B
$5.03M 5.28%
158,100
– –
DGX icon
8
Quest Diagnostics
DGX
$27B
$4.8M 5.04%
66,208
-11,000
-14% -$812K
AORT icon
9
Artivion
AORT
$1.3B
$4.17M 4.38%
370,000
+149,000
+67% +$1.58M
TWM icon
10
CALL
ProShares UltraShort Russell2000
TWM
$44M
$3.48M 3.65%
+5,000
New +$3.51M
TWM icon
11
ProShares UltraShort Russell2000
TWM
$44M
$3.48M 3.65%
5,000
-5,000
-50% -$3.51M
AGN
12
DELISTED
Allergan plc
AGN
$3.04M 3.19%
10,000
– –
BIS icon
13
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$2.87M 3.02%
12,500
– –
ADYX
14
DELISTED
Adynxx Inc
ADYX
$2.22M 2.33%
7,017
+3,750
+115% +$1.11M
VIRX
15
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.11M 2.21%
3,333
+2,381
+250% +$1.27M
ABBV icon
16
AbbVie
ABBV
$456B
$1.68M 1.76%
+25,000
New +$1.63M
AEGR
17
DELISTED
Aegerion Pharmaceuticals
AEGR
$1.52M 1.59%
80,000
+55,000
+220% +$1.19M
VIXY icon
18
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$212M
$1.34M 1.41%
+63
New +$1.36M
SEEL
19
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$1.11M 1.17%
+1
New +$1.91M
AMRN
20
CALL
Amarin Corp
AMRN
$299M
$984K 1.03%
20,000
+10,000
+100% +$450K
SRNE
21
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$881K 0.93%
50,000
-75,000
-60% -$964K
SUPN icon
22
CALL
Supernus Pharmaceuticals
SUPN
$2.57B
$849K 0.89%
+50,000
New +$712K
FCSC
23
DELISTED
Fibrocell Science Inc.
FCSC
$831K 0.87%
10,518
– –
ARIA
24
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$827K 0.87%
100,000
-50,000
-33% -$442K
CYTK icon
25
Cytokinetics
CYTK
$10.8B
$672K 0.71%
100,000
– –
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Healthcare Value Capital held 42 positions worth $95.2M, up 3.8% from $91.8M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Healthcare Value Capital's Q2 2015 filing shows 7 new, 9 increased, 5 reduced and 12 closed positions. Its largest new stake was ANI Pharmaceuticals: 125,000 shares worth $7.76M. The largest sale was Teva Pharmaceuticals, an estimated $6.23M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 61% a quarter earlier, followed by Miscellaneous.

  • Healthcare Value Capital's largest Q2 2015 buy was ANI Pharmaceuticals: 125,000 shares worth $7.76M.
  • Healthcare Value Capital added most to QLT Inc in Q2 2015, an estimated $4.59M increase.
  • Healthcare Value Capital's biggest Q2 2015 reduction was ProShares UltraShort Russell2000, cutting an estimated $3.51M.
  • Healthcare Value Capital fully exited Teva Pharmaceuticals in Q2 2015, selling an estimated $6.23M.
  • Healthcare Value Capital's ten largest holdings make up 72% of its $95.2M portfolio in Q2 2015.
  • Healthcare Value Capital opened 7 new positions and closed 12 in Q2 2015.
  • Healthcare Value Capital's portfolio value rose 3.8% quarter-over-quarter to $95.2M.

Based on Healthcare Value Capital's 13F filing for Q2 2015, filed 14 Aug 2015.